Abstract
..
Main
..
RCT vs. Obs.
..
Feedback
Home
c19early.org COVID-19 treatment researchColchicineColchicine (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta
Home Adoption Other Treatments
@CovidAnalysis
Loading...
 
Analgesics⏵
Antiandrogens⏵
Antihistamines⏵
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Monoclonals⏵
Mpro inhibitors⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors⏵
TMPRSS2 inh.⏵
Thermotherapy
Vitamins⏵
More⏵
 

Supplementary Data — Colchicine reduces COVID-19 risk: real-time meta analysis of 57 studies

@CovidAnalysis, May 2025, Version 65V65
PDF
All
Studies
All
Treatments
Feedback
https://c19early.org/ometa.html
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Hunt 68% 0.32 [0.15-0.67] death Improvement, RR [CI] Treatment Control Hassan (RCT) -40% 1.40 [0.48-4.12] hosp. 7/50 5/50 Hassan (RCT) 4% 0.96 [0.68-1.37] no recov. 27/50 28/50 Inokuchi (RCT) 67% 0.33 [0.03-3.29] hosp. 1/23 2/15 OT​1​ CT​2​ Inokuchi (RCT) 24% 0.76 [0.35-1.67] no recov. 8/21 6/12 OT​1​ CT​2​ Inokuchi (RCT) -17% 1.17 [0.66-2.07] recov. time 21 (n) 12 (n) OT​1​ CT​2​ GRECCO-19 Deftereos (RCT) 77% 0.23 [0.03-1.97] death 1/55 4/50 GRECCO-19 Deftereos (RCT) 82% 0.18 [0.02-1.50] ventilation 1/55 5/50 GRECCO-19 Deftereos (RCT) 87% 0.13 [0.01-0.97] progression 1/55 7/50 Lopes (DB RCT) 80% 0.20 [0.01-4.03] death 0/36 2/36 Lopes (DB RCT) 50% 0.50 [0.10-2.56] ICU 2/36 4/36 Lopes (DB RCT) 22% 0.78 [0.64-0.94] hosp. time 36 (n) 36 (n) Brunetti (PSM) 73% 0.27 [0.08-0.89] death 3/33 11/33 Brunetti (PSM) 73% 0.27 [0.08-0.89] no disch. 3/33 11/33 Scarsi 85% 0.15 [0.06-0.37] death 122 (n) 140 (n) Salehzadeh (RCT) 23% 0.77 [0.66-0.90] hosp. time 50 (n) 50 (n) Pinzón 35% 0.65 [0.34-1.21] death 14/145 23/156 Sandhu 42% 0.58 [0.40-0.85] death 16/34 63/78 Sandhu 53% 0.47 [0.33-0.67] ventilation 16/34 68/68 Sandhu 42% 0.58 [0.40-0.85] no disch. 16/34 63/78 Rodriguez-Nava 6% 0.94 [0.61-1.47] death 16/52 85/261 Mahale -7% 1.07 [0.59-1.96] death 11/39 25/95 Valerio Pas.. (ICU) 23% 0.77 [0.31-1.94] death 5/35 12/30 ICU patients CT​2​ Valerio Pas.. (ICU) 40% 0.60 [0.38-0.95] ICU 35 (n) 30 (n) ICU patients CT​2​ COLCORONA Tardif (DB RCT) 44% 0.56 [0.19-1.67] death 5/2,235 9/2,253 COLCORONA Tardif (DB RCT) 20% 0.80 [0.62-1.03] death/hosp. 104/2,235 131/2,253 COLCORONA Tardif (DB RCT) 47% 0.53 [0.25-1.09] ventilation 11/2,235 21/2,253 COLCORONA Tardif (DB RCT) 20% 0.80 [0.61-1.03] hosp. 101/2,235 128/2,253 Mareev 80% 0.20 [0.01-4.01] death 0/21 2/22 Mareev 50% 0.50 [0.24-1.04] no recov. 21 (n) 22 (n) Mareev 71% 0.29 [0.13-0.63] no recov. 21 (n) 22 (n) Mareev 67% 0.33 [0.10-1.07] no recov. 21 (n) 22 (n) Mareev 26% 0.74 [0.53-1.04] hosp. time 21 (n) 22 (n) García-Posada 57% 0.43 [0.16-0.84] death 48/99 59/110 CT​2​ Manenti (PSW) 76% 0.24 [0.09-0.67] death 71 (n) 70 (n) Manenti (PSW) 44% 0.56 [0.31-1.00] no recov. 71 (n) 70 (n) Mostafaie (RCT) 83% 0.17 [0.02-1.34] death 1/60 6/60 CT​2​ Mostafaie (RCT) 35% 0.65 [0.53-0.81] hosp. time 59 (n) 54 (n) CT​2​ RECOVERY Recovery C.. (RCT) -1% 1.01 [0.93-1.10] death 1,173/5,610 1,190/5,730 RECOVERY Recovery C.. (RCT) -18% 1.18 [0.99-1.40] ventilation 259/3,815 228/3,962 RECOVERY Recovery C.. (RCT) -2% 1.02 [0.96-1.09] death/int. 1,344/5,342 1,343/5,469 RECOVERY Recovery C.. (RCT) -2% 1.02 [0.97-1.06] no disch. 1,709/5,610 1,698/5,730 Hueda-Zavaleta 54% 0.46 [0.23-0.91] death 10/50 109/301 Kevorkian 96% 0.04 [0.01-0.21] progression 28 (n) 40 (n) CT​2​ Gaitán-Dua.. (RCT) 22% 0.78 [0.44-1.36] death 22/153 28/161 CT​2​ Pascual-Fi.. (RCT) 80% 0.20 [0.01-4.03] death 0/52 2/51 Pascual-Fi.. (RCT) 80% 0.20 [0.01-4.03] ventilation 0/52 2/51 Pascual-Fi.. (RCT) 51% 0.49 [0.09-2.56] ICU 2/52 4/51 Pascual-Fi.. (RCT) 87% 0.13 [0.01-0.71] 7-point status 3/52 7/51 Pascual-Fi.. (RCT) 80% 0.20 [0.01-4.03] 7-point status 0/52 2/51 Pascual-Fi.. (RCT) -15% 1.15 [0.87-1.51] hosp. time 52 (n) 51 (n) PRINCIPLE Dorward (RCT) 70% 0.30 [0.01-7.37] death 0/156 1/120 PRINCIPLE Dorward (RCT) -30% 1.30 [0.42-3.84] death/hosp. 6/156 4/133 PRINCIPLE Dorward (RCT) 22% 0.78 [0.30-1.73] death/hosp. 6/156 119/1,145 PRINCIPLE Dorward (RCT) -6% 1.06 [0.81-1.39] no recov. 156 (n) 133 (n) Absalón-.. (DB RCT) 29% 0.71 [0.21-2.40] death 4/56 6/60 Absalón-.. (DB RCT) 17% 0.83 [0.35-1.93] progression 56 (n) 60 (n) Absalón-.. (DB RCT) -13% 1.13 [0.76-1.66] no recov. 56 (n) 60 (n) Diaz (RCT) 12% 0.88 [0.70-1.12] death 131/640 142/639 Diaz (RCT) 17% 0.83 [0.67-1.02] death/int. 160/640 184/639 Diaz (RCT) 52% 0.48 [0.18-1.27] death/int. 6/93 13/102 Diaz (RCT) 17% 0.83 [0.64-1.07] death 98/515 140/634 Diaz (RCT) 25% 0.75 [0.60-0.95] death/int. 117/515 181/634 Alsultan (RCT) 36% 0.64 [0.20-2.07] death 3/14 7/21 Karakaş 13% 0.87 [0.46-1.64] death 16/165 19/171 Karakaş 16% 0.84 [0.55-1.29] ICU 30/165 37/171 Karakaş 25% 0.75 [0.65-0.87] hosp. time 165 (n) 171 (n) Pourdowlat (RCT) 73% 0.27 [0.11-0.71] hosp. 5/102 18/100 Pourdowlat (RCT) 38% 0.62 [0.41-0.94] no recov. 89 (n) 63 (n) Pourdowlat (RCT) 22% 0.78 [0.60-1.00] no recov. 89 (n) 63 (n) Gorial (RCT) 67% 0.33 [0.04-3.14] death 1/80 3/80 Gorial (RCT) 63% 0.37 [0.21-0.67] no recov. 80 (n) 80 (n) STRUCK Pimenta B.. (RCT) 79% 0.21 [0.01-4.05] death 0/14 2/16 STRUCK Pimenta B.. (RCT) 85% 0.15 [0.01-2.69] no improv. 0/14 3/16 Jalal (RCT) 24% 0.76 [0.62-0.93] hosp. time 36 (n) 44 (n) Cecconi (DB RCT) 29% 0.71 [0.28-1.79] death 7/119 10/120 Cecconi (DB RCT) 50% 0.50 [0.18-1.43] ventilation 5/119 10/120 Cecconi (DB RCT) 21% 0.79 [0.38-1.67] ICU 11/119 14/120 Cecconi (DB RCT) 15% 0.85 [0.50-1.43] NIV/ICU/vent./death 21/119 25/120 ACT inpatient Eikelboom (RCT) -8% 1.08 [0.91-1.29] death 264/1,304 249/1,307 ACT inpatient Eikelboom (RCT) -4% 1.04 [0.90-1.21] progression 368/1,304 356/1,307 ACT inpatient Eikelboom (RCT) 2% 0.98 [0.82-1.17] progression 246/1,304 252/1,307 ACT outpatient Eikelboom (RCT) -9% 1.09 [0.48-2.47] death 12/1,939 11/1,942 ACT outpatient Eikelboom (RCT) -2% 1.02 [0.72-1.43] death/hosp. 66/1,939 65/1,942 ACT outpatient Eikelboom (RCT) -2% 1.02 [0.71-1.45] hosp. 62/1,939 61/1,942 COLVID-19 Perricone (RCT) -36% 1.36 [0.45-4.11] death 7/77 5/75 COLVID-19 Perricone (RCT) -7% 1.07 [0.48-2.37] progression 11/77 10/75 COLVID-19 Perricone (RCT) -30% 1.30 [0.30-5.61] ventilation 4/77 3/75 COLVID-19 Perricone (RCT) 76% 0.24 [0.03-2.13] ICU 1/77 4/75 COLVID-19 Perricone (RCT) 4% 0.96 [0.79-1.17] hosp. time 77 (n) 75 (n) Rahman (DB RCT) 71% 0.29 [0.10-0.92] death 4/146 13/146 Rahman (DB RCT) 71% 0.29 [0.10-0.92] progression 4/146 13/146 Rahman (DB RCT) 61% 0.39 [0.08-2.02] death 2/146 5/146 Rahman (DB RCT) 51% 0.49 [0.09-2.68] ventilation 2/146 4/146 Rahman (DB RCT) 56% 0.44 [0.13-1.43] progression 4/146 9/146 Hueda-Zavaleta -33% 1.33 [0.75-2.36] death 18/52 33/148 Ventilated patients Haroon (RCT) 34% 0.66 [0.40-1.10] no recov. 48 (n) 48 (n) Kasiri (DB RCT) 7% 0.93 [0.32-2.69] death 6/55 6/51 Kasiri (DB RCT) 7% 0.93 [0.32-2.69] ventilation 6/55 6/51 Kasiri (DB RCT) -24% 1.24 [0.57-2.69] ICU 12/55 9/51 Kasiri (DB RCT) 28% 0.72 [0.29-1.79] no recov. 7/55 9/51 Kasiri (DB RCT) 12% 0.88 [0.55-1.43] no recov. 20/55 21/51 Kasiri (DB RCT) 14% 0.86 [0.73-1.01] recov. time 55 (n) 51 (n) Sunil Naik (RCT) -169% 2.69 [0.11-64.6] death 1/62 0/43 Sunil Naik (RCT) -108% 2.08 [0.22-19.3] progression 3/62 1/43 Sunil Naik (RCT) 7% 0.93 [0.82-1.04] no recov. 62 (n) 43 (n) Sunil Naik (RCT) 15% 0.85 [0.72-1.01] no recov. 49/62 40/43 Sunil Naik (RCT) 24% 0.76 [0.60-0.95] no recov. 62 (n) 43 (n) COLSTAT Shah (RCT) -75% 1.75 [0.53-5.83] death 7/125 4/125 CT​2​ COLSTAT Shah (RCT) -100% 2.00 [0.51-7.82] death 6/125 3/125 CT​2​ COLSTAT Shah (RCT) -200% 3.00 [0.62-14.6] ventilation 6/125 2/125 CT​2​ COLSTAT Shah (RCT) -46% 1.46 [0.76-2.83] severe case 19/125 13/125 CT​2​ COLSTAT Shah (RCT) -73% 1.73 [0.86-3.48] severe case 19/125 11/125 CT​2​ Villamañán 42% 0.58 [0.33-0.96] death 19/111 32/111 Mehrizi -13% 1.13 [1.08-1.19] death population-based cohort Yadollahza.. (RCT) 33% 0.67 [0.28-1.60] death 6/26 9/26 Vaziri (RCT) 81% 0.19 [0.04-0.88] death 2/108 7/71 CT​2​ Vaziri (RCT) 89% 0.11 [0.01-0.89] death 1/108 6/71 CT​2​ Vaziri (RCT) 87% 0.13 [0.03-0.58] ICU 2/108 10/71 CT​2​ Vaziri (RCT) 35% 0.65 [0.58-0.73] hosp. time 108 (n) 71 (n) CT​2​ COLTREXONE Gertner (RCT) 65% 0.35 [0.10-1.27] ICU 67 (n) 70 (n) COLTREXONE Gertner (RCT) 43% 0.57 [0.27-1.20] no recov. 67 (n) 70 (n) COLTREXONE Gertner (RCT) 24% 0.76 [0.55-1.10] no recov. 67 (n) 70 (n) COLTREXONE Gertner (RCT) 34% 0.66 [0.28-1.53] oxygen 67 (n) 70 (n) COLTREXONE Gertner (RCT) 20% 0.80 [0.59-1.07] hosp. time 67 (n) 70 (n) CONVINCE Landi (RCT) -4% 1.04 [0.06-16.6] hosp. 30 (n) 29 (n) CONVINCE Landi (RCT) -5% 1.05 [0.07-16.7] oxygen 30 (n) 29 (n) CONVINCE Landi (RCT) 40% 0.60 [0.23-1.54] misc. 30 (n) 29 (n) CONVINCE Landi (RCT) 11% 0.89 [0.41-1.93] viral+ 30 (n) 29 (n) Madrid-García -37% 1.37 [0.48-3.90] death n/a n/a Madrid-García -137% 2.37 [0.64-8.73] hosp. n/a n/a Ozcifci 4% 0.96 [0.75-1.22] cases 130/616 85/421 Monserrat .. (PSM) 80% 0.20 [0.02-0.93] death n/a n/a Topless 23% 0.77 [0.56-1.07] death population-based cohort Oztas -406% 5.06 [0.59-43.2] hosp. 5/635 1/643 Oztas -73% 1.73 [0.96-3.11] symp. case 29/635 17/643 Oztas -24% 1.24 [0.81-1.92] cases 43/635 35/643 Avanoglu Guler 79% 0.21 [0.04-0.83] oxygen 6/66 3/7 Correa-Rodríguez -150% 2.50 [0.10-60.6] oxygen 1/163 0/81 Correa-Rodríguez -150% 2.50 [0.10-60.6] hosp. 1/163 0/81 Correa-Rodríguez 7% 0.93 [0.51-1.70] no recov. 13/24 7/12 Correa-Rodríguez 1% 0.99 [0.52-1.88] cases 24/163 12/81 Sáenz-Aldea -8% 1.08 [0.76-1.53] hosp. case control Sáenz-Aldea -12% 1.12 [0.91-1.37] cases case control Chevalier -28% 1.28 [0.51-2.35] death 5/21 111/569 Chevalier 8% 0.92 [0.36-1.78] hosp. 15/116 180/1,097 Colchicine COVID-19 outcomes c19early.org May 2025 ​1​ OT: comparison with other treatment​2​ CT: study uses combined treatment Favors colchicine Favors control
Figure S1. All outcomes.
Loading..
Figure S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0